ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Acurx Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.14+0.04 (+3.64%)

Close on Oct 19, 2026

Market cap: $4.86M
P/E (TTM): –
Dividend yield: –

Acurx Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	7.56	3.71	7.47	9.11	13	3.18	2.48
Cash & Short-Term Investments	7.56	3.71	7.47	9.11	13	3.18	2.48
Prepaid Expenses & Other	0.09	0.10	0.11	0.26	0.30	0.05	–
Total Current Assets	–	3.86	7.71	9.38	13	–	–
Total Assets	7.69	3.86	7.71	9.38	13	3.22	–
Accounts Payable	2.42	3.24	3.04	2.06	0.84	0.46	–
Total Current Liabilities	2.42	3.24	3.04	2.06	0.84	0.47	–
Total Liabilities	2.42	3.24	3.04	2.06	0.84	0.52	–
Common Stock	0.00	0.00	0.01	0.01	0.01	–	–
Additional Paid-In Capital	81	68	58	46	39	–	–
Retained Earnings	-75	-67	-53	-39	-27	-14	–
Shareholders' Equity	5.27	0.62	4.67	7.32	12	2.70	–
Total Equity	5.27	0.62	4.67	7.32	12	2.70	–
Total Liabilities & Equity	7.69	3.86	7.71	9.38	13	3.22	–
Shares Outstanding(shares)	2.35	0.85	0.72	0.58	0.51	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -270.8%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 376.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.60
Dividend yield: –